
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. exhibits a promising outlook due to the sustained reduction in TRAb levels during the off-treatment period, indicating the potential disease-modifying effects of its FcRn inhibitors in treating Graves' disease (GD). The company demonstrated an impressive responder rate of 81% during the 6-month off-treatment period, which aligns closely with the 70%-80% responder rates observed during active treatment. This consistency reinforces confidence in the durability of the treatment's effectiveness, especially in patients not responsive to antithyroid drug therapy, thus highlighting the robustness of Immunovant's product candidates.
Bears say
Immunovant Inc faces a challenging outlook due to the persistent high levels of TRAbs, which are linked to increased rates of relapse in patients. This implies potential efficacy concerns regarding their primary focus, IMVT-1402, as the interplay between TRAbs and the growth factor pathways has implications for the effectiveness of the treatment. The clinical risk of serious complications, including inflammation and vision threats stemming from TRAbs-mediated interactions, adds further uncertainty to the company's development efforts and market viability.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares